Akebia Therapeutics
AKBA
3 hedge funds and large institutions have $2.03M invested in Akebia Therapeutics in 2014 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$1.31M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$484K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$389K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GGHC
1
Gilder Gagnon Howe & Co
New York
| $1.22M | +$1.31M | +62,380 | New |
|
|
LCM
2
Laurion Capital Management
New York
| $449K | +$484K | +22,975 | New |
|
|
3
Citadel Advisors
Miami,
Florida
| $361K | +$389K | +18,448 | New |
|
AKBA Hedge Fund Activity: Q1 2014 in Review
3 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2014, worth a combined $2.03M.
Buyers outnumbered sellers: 3 funds opened new AKBA positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Gilder Gagnon Howe & Co, opening a new position worth an estimated $1.31M.
- 3 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $2.03M of Akebia Therapeutics stock for Q1 2014.
- 3 funds opened new Akebia Therapeutics positions in Q1 2014 and 0 closed out, a net change of +3 holders.
- The largest Akebia Therapeutics buyer in Q1 2014 was Gilder Gagnon Howe & Co, an estimated $1.31M added.
Based on aggregated 13F filings for Q1 2014.